Opendata, web and dolomites

Super-Vaccine SIGNED

Exploring the potential applications of live viral vaccine encoded small-hairpin-RNAs in improving both vaccine safety and efficacy through RNA-interference and stimulation of the innate immune system

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Super-Vaccine project word cloud

Explore the words cloud of the Super-Vaccine project. It provides you a very rough idea of what is the project "Super-Vaccine" about.

attenuated    interferon    tomorrow    security    spread    trials    primary    appropriately    doses    intrinsic    inhibit    live    wild    lower    interventions    expression    herpesvirus    roadmap    instrumental    harmony    beneficial    efficacy    rna    viral    interference    modifying    ifn    manufacturing    levels    safety    propagation    reducing    ultimately    exclusively    food    innovation    launched    innate    explored    virus    stimulation    feasible    immune    progression    replication    potent    shrnas    disease    vaccine    ongoing    strategy    economically    reduce    circulating    recombination    vaccination    basis    occurrences    recombine    healthcare    perspective    2016    programs    viruses    followed    mind    small    global    functioning    rnas    hairpin    vitro    desirable    capacity    strains    priorities    express    vivo    cyprinid    rnai    market    inducers    outline    explore    strain    designed    genetically    vaccines    societal    efforts    potency    strategic    wt    meet   

Project "Super-Vaccine" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE LIEGE 

Organization address
address: PLACE DU 20 AOUT 7
city: LIEGE
postcode: 4000
website: www.ulg.ac.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 160˙800 €
 EC max contribution 160˙800 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-CAR
 Starting year 2018
 Duration (year-month-day) from 2018-09-19   to  2020-09-18

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE LIEGE BE (LIEGE) coordinator 160˙800.00

Map

 Project objective

Live vaccines represent one of the most important and effective interventions against the spread of viral disease. As such, they are instrumental in addressing ongoing societal challenges in areas such as healthcare and global food security. However, their capacity to genetically recombine with wild type (WT) viruses circulating in the field remains a primary safety concern. Modifying live vaccine strains to reduce such occurrences would be highly desirable from a safety perspective. Also efforts to enhance the intrinsic potency of vaccine strains would be very beneficial. This would facilitate the use of much lower doses, while reducing the manufacturing resources required to meet market needs and the cost of vaccination programs.

With this in mind, this project will explore a novel strategy to improve both the safety and efficacy of live viral vaccine strains by modifying them to express small-hairpin-RNAs (shRNAs), which can be designed to:

i) Exclusively inhibit WT virus replication/propagation via RNA-interference (RNAi), thus reducing the levels of WT available for recombination with vaccine strains during vaccination i.e. improving safety

ii) Increase live vaccine strain stimulation of the innate immune system by functioning as potent inducers of Type-1 Interferon (IFN-I) expression during vaccination i.e. enhancing efficacy

This novel strategy will be explored by modifying an existing attenuated Cyprinid herpesvirus-3 vaccine strain to express appropriately designed shRNAs, followed by an assessment of their impact on both WT virus replication and IFN-I expression in-vitro, providing a basis for future progression to in-vivo trials.

Ultimately, if feasible, this novel vaccine design strategy may be applied in the control of many economically important viruses. Also elements of this project are in harmony with the “Strategic European Roadmap for the Vaccines of Tomorrow” launched in 2016 to outline specific EU priorities in future vaccine innovation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPER-VACCINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SUPER-VACCINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

TIPTOP (2019)

Tensoring Positive Maps on Operator Structures

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

STRESS-Mums (2019)

Study on TRansition and Exclusion in Society of Single-Mums

Read More